AMRX (Amneal Pharmaceuticals) COGS-to-Revenue : 0.63 (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals COGS-to-Revenue?

Amneal Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2025 was $440 Mil. Its Revenue for the three months ended in Mar. 2025 was $695 Mil.

Amneal Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2025 was 0.63.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Amneal Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2025 was 36.80%.

Amneal Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Amneal Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals COGS-to-Revenue Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.68

0.63

0.65

0.66

0.63

Amneal Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.64	0.64	0.62	0.64	0.63

Amneal Pharmaceuticals COGS-to-Revenue Calculation

Amneal Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1773.519	/	2793.957
	=	0.63

Amneal Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	439.529	/	695.42
	=	0.63

Amneal Pharmaceuticals (NAS:AMRX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Amneal Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	439.529 / 695.42
	=	36.80 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Amneal Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Amneal Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website

https://www.amneal.com

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Executives

Nikita Shah	officer: SVP, Chief HR Officer	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
John Kiely	director	C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Gautam Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Tushar Bhikhubhai Patel	10 percent owner	C/O TARSADIA INVESTMENTS, 520 NEWPORT CENTER DRIVE, 21ST FLOOR, NEWPORT BEACH CA 92660
Andrew S Boyer	officer: Exec VP, Comm Optns	C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Tasos Konidaris	officer: SVP and CFO	103 JFK PARKWAY, SHORT HILLS NJ 07078
Deborah M. Autor	director	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Jason B. Daly	officer: SVP, Chief Legal Officer	400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin	officer: See Remarks	4 PARK LANE, MADISON NJ 07940
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Chirag K. Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco	officer: SVP, Specialty Commercial	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807